Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping ...

ALX Nigeria has unveiled Creative Tech Lite, a new initiative designed to equip the continent’s creators with in-demand digital skills.

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...